Jubilant Life Sciences Q3 net loss at Rs 11.16 crore
Its net sales stood at Rs 1,430.25 crore during the period, marginal increase of 0.18 per cent per cent compared to Rs 1,427.65 crore y-o-y.
By PTI | Updated:
NEW DELHI: Jubilant Life Sciences today posted a consolidated net loss of Rs 11.16 crore for the third quarter ended December 31, 2014.
The company had a net profit of Rs 143.43 crore during the same period of previous fiscal.
Its net sales for the quarter under review stood at Rs 1,430.25 crore during the period, marginal increase of 0.18 per cent per cent compared to Rs 1,427.65 crore in the same period previous fiscal.
Commenting on the result, Jubilant Life Sciences, Chairman and Managing Director Shyam S Bhartia said: ".. Our overall business performance is showing signs of recovery, post the challenges of last six months.
"Some of the key businesses witnessed healthy profitable growth from the preceding quarter, led by growth in our radiopharmaceutical business and resumption of operations in CMO (contract manufacturing) business."
He further said: "Our management consolidation of Pharmaceuticals and Life Science Ingredients segments is complete with the appointment of separate CEOs to focus on growth in the respective segments."
Shares of Jubilant Life Sciences closed at Rs 172.15 apiece, up 1.09 per cent from previous close on BSE.
The company had a net profit of Rs 143.43 crore during the same period of previous fiscal.
Its net sales for the quarter under review stood at Rs 1,430.25 crore during the period, marginal increase of 0.18 per cent per cent compared to Rs 1,427.65 crore in the same period previous fiscal.
Commenting on the result, Jubilant Life Sciences, Chairman and Managing Director Shyam S Bhartia said: ".. Our overall business performance is showing signs of recovery, post the challenges of last six months.
"Some of the key businesses witnessed healthy profitable growth from the preceding quarter, led by growth in our radiopharmaceutical business and resumption of operations in CMO (contract manufacturing) business."
He further said: "Our management consolidation of Pharmaceuticals and Life Science Ingredients segments is complete with the appointment of separate CEOs to focus on growth in the respective segments."
ADVERTISEMENT
Shares of Jubilant Life Sciences closed at Rs 172.15 apiece, up 1.09 per cent from previous close on BSE.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
Related Articles
Jubilant Life Sciences Q3 net profit down 24% to Rs 203.38 croreADVERTISEMENT
